AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment
LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen...